These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. A conceptual framework for the use of neuroimaging to study and predict pharmacoresistance in epilepsy. Pohlmann-Eden B; Crocker CE; Schmidt MH Epilepsia; 2013 May; 54 Suppl 2():75-9. PubMed ID: 23646977 [TBL] [Abstract][Full Text] [Related]
11. Summary of the Eleventh Eilat Conference on New Antiepileptic Drugs and inauguration of editors' choice open access articles in epilepsy research. Treiman DM Epilepsy Res; 2013 Jan; 103(1):1. PubMed ID: 23265715 [No Abstract] [Full Text] [Related]
12. Design of innovative therapeutics for pharmacoresistant epilepsy: challenges and needs. Weaver DF Epilepsia; 2013 May; 54 Suppl 2():56-9. PubMed ID: 23646972 [TBL] [Abstract][Full Text] [Related]
13. Antiepileptic drug treatment 2011; current limitations and future perspectives. Boon PA Seizure; 2011 Jun; 20(5):357-8. PubMed ID: 21498088 [No Abstract] [Full Text] [Related]
14. Response to antiepileptic drug therapy: winners and losers. Brodie MJ Epilepsia; 2005; 46 Suppl 10():31-2. PubMed ID: 16359468 [TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy of epilepsy: new armamentarium, new issues. Vajda FJ J Clin Neurosci; 2007 Sep; 14(9):813-23. PubMed ID: 17618119 [TBL] [Abstract][Full Text] [Related]
16. Pharmacoresistant epilepsy: from pathogenesis to current and emerging therapies. Pati S; Alexopoulos AV Cleve Clin J Med; 2010 Jul; 77(7):457-67. PubMed ID: 20601619 [TBL] [Abstract][Full Text] [Related]
17. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Remy S; Beck H Brain; 2006 Jan; 129(Pt 1):18-35. PubMed ID: 16317026 [TBL] [Abstract][Full Text] [Related]
19. The potential of pharmacogenetics in the treatment of epilepsy. Depondt C Eur J Paediatr Neurol; 2006 Mar; 10(2):57-65. PubMed ID: 16531088 [TBL] [Abstract][Full Text] [Related]